Revised manuscript 10-6-15

Title: The *APOE4* allele shows opposite sex bias in microbleeds and Alzheimer's Disease of humans and mice

Authors: Mafalda Cacciottolo^a, Amy Christensen^a, Alexandra Moser^a, Jiahui Liu^a, Christian J. Pike^a, Patrick M. Sullivan^d, Todd E. Morgan^a, Egor Dolzhenko^c, Andreas Charidimou^e, Lars-Olaf Wahlund^f, Maria Kristofferson Wiberg^g, Sara Shams^g, Gloria Chia-Yi Chiang^{h†}, Caleb E. Finch^{a,b,c*}

Affiliations:

^aDavis School of Gerontology, University of Southern California, Los Angeles, CA, USA

^bDepartment of Biological Sciences, Dornsife College, University of Southern California, Los Angeles, CA

^cDepartment of Molecular and Computational Biology, University of Southern California, Los Angeles, CA

^dDepartment of Medicine, Duke University, Durham VA Medical Center and GRECC, Durham, NC

^eHemorrhagic Stroke Research Program, Department of Neurology, Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston, MA, USA

^fDepartment of Neurobiology, Care Sciences, and Society, Karolinska Institutet, Stockholm, Sweden. Division of Clinical Geriatrics, Karolinska University Hospital, Stockholm, Sweden

^gDepartment of Clinical Science, Intervention, and Technology, Division of Medical Imaging and Technology, Karolinska Institutet, Stockholm, Sweden. Department of Radiology, Karolinska University Hospital, Stockholm, Sweden

^hDepartment of Radiology, Weill Cornell Medical College, New York, N.Y.

[†]For the Alzheimer's Disease Neuroimaging Initiative (ADNI).

***Corresponding author:** Caleb Finch, cefinch@usc.edu, Davis School of Gerontology and Dept of Neurobiology in the Dornsife College, University of Southern California, Los Angeles, CA 90089-0191.

Abstract.

The *APOE4* allele confers greater risk of Alzheimer's Disease (AD) for women than men, in conjunction with greater clinical deficits per unit of AD neuropathology (plaques, tangles). Cerebral microbleeds, which contribute to cognitive dysfunctions during AD, also show *APOE4* excess, but sex-APOE allele interactions are not described. We report that elderly men diagnosed for mild cognitive impairment (MCI) and AD showed a higher risk of cerebral cortex microbleeds with *APOE4* allele dose effect in two clinical cohorts (ADNI and KIDS). Sex-APOE interactions were further analyzed in EFAD mice carrying human APOE alleles and familial AD genes. At 7 months, E4FAD mice had cerebral cortex microbleeds with female excess, in contrast to humans. Cerebral amyloid angiopathy (CAA), plaques, and soluble A β also showed female excess. Both the cerebral microbleeds and CAA increased in proportion to individual A β load. In humans, the opposite sex bias of *APOE4* allele for microbleeds vs the plaques and tangles is the first example of organ-specific, sex-linked APOE allele effects, and further shows AD as a uniquely human condition.

Keywords

ADNI, Alzheimer's Disease Neuroimaging Initiative; Alzheimer's Disease, AD; A β , amyloid β -peptide; APOE, apolipoprotein E; CAA, cerebral amyloid angiopathy; EFAD mice; KIDS, Karolinska Institute Dementia Study; microbleeds, cerebral cortex microbleeds or microhemorrhages; sex bias.

Highlights

*Elderly humans with MCI and AD had male sex-*APOE4* bias for microbleeds, opposite to female A β bias

*E4FAD mice had female bias of microbleeds and A β

*In EFAD mice, CAA and microbleeds increase proportionately with A β

1. Introduction

The *APOE4* allele is the strongest heritable risk factor for sporadic AD, with sex-bias of >50% for women (Altmann et al., 2014; Farrer et al., 1997; Payami et al., 1996). The neuropathological load showed parallel sex and APOE differences in benchmark postmortem studies of AD brains, with female excess of senile plaques and of neurofibrillary tangles (NFT) (Barnes et al., 2005; Corder et al., 2004). Moreover, women incurred 5-fold greater cognitive deficits per unit of brain β -amyloid ($A\beta$) than men (Barnes et al., 2005). Other studies also show female excess vulnerability in brain aging, with 1-1.5% faster brain atrophy in MRI studies of probable AD (Hua et al., 2010), and higher tau in cerebrospinal fluid of prodromal AD (MCI) (Altmann et al., 2014), but also in cognitively healthy elderly (Damoiseaux et al., 2012). Correspondingly, women *APOE4* carriers had excess of $A\beta$ plaque and NFT (Barnes et al., 2005; Corder et al., 2004) and more hippocampal atrophy in prodromal AD (Fleisher et al., 2005). Mouse transgenic models of AD with familial AD mutations (FAD) have shown consistent female excess of brain $A\beta$ and cognitive deficits (Carroll et al., 2010; Dubal et al., 2012; Sturchler-Pierrat and Staufenbiel, 2000; Vest and Pike, 2013).

In contrast to brain $A\beta$ and NFT, cerebral cortex microbleeds (microhemorrhages) typically show male 50% excess, e.g. in the Karolinska Imaging Dementia Study (KIDS) for AD (Shams et al., 2015) and the Amsterdam Dementia Cohort (Benedictus et al., 2015). Microbleeds, together with CAA (Shams et al., 2015), are of emerging importance as a contributing factor to pre-clinical cognitive decline and as an additional clinical burden in AD (Meier et al., 2014; Reijmer et al., 2015). In cognitively normal elderly, the presence of cerebral cortex microbleeds was associated with lower resting-state cerebral blood flow and subtle cognitive deficits (Gregg et al., 2015). *APOE4* is also associated with cerebral microbleeds (Rannikmae et al., 2013; Yates et al., 2014) and CAA in leptomeningeal and cerebral cortex vessels (Rannikmae et al., 2013; Schmechel et al., 1993). Because microbleeds are associated with CAA (Premkumar et al., 1996; Yates et al., 2014), it is cogent to evaluate their association with sex. Some postmortem studies show a slight female excess of CAA (Lee and Stemmermann, 1978; Masuda et al., 1988) that was not seen in other samples (Gilbert and Vinters, 1983; Love et al., 2003; Allen et al., 2014). FAD mice develop CAA (Fryer et al., 2005) but sex differences and interactions of FAD with human APOE transgenes are not reported.

AD may have uniquely evolved in humans, because no FAD rodent or aging primate has clinical grade AD-like cognitive impairment with major neuron loss (Finch and Austad, 2015). While aging great apes develop CAA (Gearing et al., 1994) and incur sporadic strokes (Rosen et al., 2008; Jean et al., 2012), no aging wildtype rodent has shown CAA or stroke (Sullivan et al., 2008). Wildtype rodents are famously resistant to diet-induced atherosclerosis, unless made hypercholesterolemic by lipoprotein gene knockout, e.g. *APOE-KO* mice on high cholesterol diets developed aortic atheromas and intimal-media thickening (Smith et al., 2010). However, spontaneous cerebrovascular ischemic lesions are unknown in lab rodents even with induced hypercholesterolemia. Thus, four major pathological changes associated with human brain aging and AD have not been reported for aging wildtype rodents: brain $A\beta$ -amyloid deposits, major

neurodegeneration or neuron loss, CAA, and cerebrovascular ischemic lesions. One clue may be in APOE differences by species.

Humans have a unique multi-allele APOE system, while the primates and rodents examined so far have a single APOE isoform which resembles *APOE4* in some amino acid positions (Fullerton et al., 2000; McIntosh et al., 2012). Notably during aging, APOE-TR mice transgenic for human *APOE* by targeted replacement (knock-in) developed gross lobar hemorrhages by 18 months (41% of *APOE4-TR*; 8% of *APOE3-TR*) (Sullivan et al., 2008). Moreover, these hemorrhages were associated with classic CAA. The vascular thioflavin-positive fibrillar amyloid on wildtype background was unexpected because the endogenous murine A β has lower aggregatability than human A β (Boyd-Kimball et al., 2004). The greater prevalence of CAA in *APOE4*- vs *E3-TR* is consistent with findings from mice transgenic for the combination of FAD genes together human APOE, in which *APOE4* increased CAA and plaques above *APOE3* (Fryer et al., 2005). These studies did not examine sex differences.

To extend the correlations of A β with CAA for sex-APOE allele interactions in FAD mice and in human AD (see above), we used the EFAD mouse (Youmans et al., 2012) transgenic for human *APOE3* or *-E4* alleles (APOE-TR) (Sullivan et al., 1997) in combination with five familial AD genes, '5xFAD' (Oakley et al., 2006). The early deposition of A β in EFAD mice gives an attractive model to study quantitative relationships between CAA and the A β load at young ages before changes in sex steroids. Cerebral cortex was analyzed at age 7 months for sex-APOE interactions in microbleeds and CAA, and for correlations with plaque A β . We also assayed oligomeric A β , a driver of neurodegeneration in AD (Klein et al., 2001; Mucke and Selkoe, 2012), which has not been reported for associations with sex or APOE in mouse models. Novel sex-APOE allele interactions were found in microvascular pathologies of brain aging that differ from AD, with species differences that may arise during sexual differentiation.

2. Material and Methods

2.1. Subjects. Informed written consent was obtained from all participants at each site.

2.1.1. Alzheimer's Disease Neuroimaging Initiative (ADNI) (U.S.A. and Canada). The ADNI database (www.adni-info.org) represents a longitudinal study of MRI and PET, combined with biological markers and clinical assessment of mild cognitive impairment (MCI) and early AD. More than 1500 community dwelling subjects, aged 48 to 91 years, were recruited at 50 sites across the U.S. and Canada. Microbleeds were assessed by MRI (<http://adni.loni.usc.edu/methods/documents/mri-protocols>) as hypointense lesions within the brain parenchyma <10 mm dia. on the MRI sequence: GRE/T2*; MRI field strength: 1.5T/3.0T (Greenberg et al., 2009; Wardlaw et al., 2013). Excluding APOE2, the sample was 658 subjects (166 cognitively normal, 402 with mild cognitive impairment, and 90 with early AD).

2.1.2. Karolinska Institute Dementia Study (KIDS) cohort (Sweden). The KIDS database represents a cross-sectional cohort of consecutive patients undergoing memory investigation with an accompanying MRI scan for

hemosiderin at Karolinska University Hospital, Stockholm, Swe. (n=1572, 2006-2012, age 36 to 88 years). Informed consent: if the patient was too confused, consent was obtained from a legal guardian. Ethics approval was obtained from the regional ethics board, Stockholm. After excluding scans of insufficient quality and APOE2, the analysis cohort consisted of 448 subjects: 152 AD, 152 MCI, and 144 controls which were a group of patients with subjective cognitive impairment (not clinical grade) (Caracciolo et al., 2012). Diagnoses were set according to ICD-10 by senior geriatricians at the memory clinic in multidisciplinary meetings that considered all diagnostic analyses. MRI scans were made on 1.5–3.0T scanners with full protocols with axial hemosiderin sequences T2* and/or SWI. Microbleeds were characterized by the microbleed anatomical rating scale and identified as hypointense lesions <10 mm dia. (Gregoire et al., 2009).

2.2. Animals. Procedures were approved by the USC Institutional Animal Care and Use Committee. EFAD mice were generously given by Mary Jo LaDu (Univ. Illinois at Chicago). E3FAD and E4FAD mice were generated by crossing 5XFAD to homozygous APOE3-, and APOE4-TR. APOE-TR mice were generated by Dr. Patrick Sullivan (Sullivan et al., 1997). 5xFAD mice are transgenic for 5 distinct FAD mutations (APP K670N/M671L+ I716V+ V717I and PS1 M146L+L286V) controlled by the neuron-specific mouse Thy-1 promoter (Oakley, et al., 2006). Mice were examined at age 6-7 mo, when the female bias in behavioral deficits emerges in NSE-APOE mouse (Raber et al., 1998). C57BL/6NJ mice were used as the background mice strain. Two different cohorts of mice were used: one (4-5 mice/group) for microbleed (Fig. 2) and one for CAA (6-7 mice/group) (Fig. 3) analysis. Both were analyzed for A β load (Fig. 4, 5).

2.3. Tissues. After euthanization by isoflurane anesthesia, mice were perfused transcardially with PBS. Brains were hemi-sectioned and fixed in 4% paraformaldehyde/24 h, immersed in sequential sucrose (10-20-30%, 24 h each) and Optimal Cutting Temperature compound (OCT, Sakura, Torrance, CA), and frozen on dry ice. The other hemisphere was dissected and stored at -80 °C. All assays used observer-blinded protocols.

2.4. Immunohistochemistry. After sagittal sectioning 0.5-2 mm from midline (25 μ m), sections were stored at -80 °C. A β amyloid was immunostained with 4G8 (residues 17-24 at N-terminal of APP; Covance, Princeton, NJ) (Rasool et al., 2013). Sections were immersed in 70% formic acid/5 min. Endogenous peroxidases were blocked by 3% H₂O₂ and 10% methanol in Tris-buffered saline (TBS), 30 min/22 °C. Sections were permeabilized in 0.1% Triton X-100/15 min, blocked by 30 min incubation in TBS with 2% BSA and 0.1% Triton, followed by primary and then biotinylated anti-mouse secondary antibodies (1:250), and stained by ABC peroxidase and DAB substrate (Vector, Burlingame, CA). For plaque quantification bright field microscopic images were converted to 8-bit grayscale, thresholded to highlight plaques and to diminish background signal with visual inspection to confirm each object as a plaque. The entire cortex

section was evaluated for total plaque number and percentage of area covered (A β load) by the “analyze particles” function of NIH ImageJ software.

Fibrillar A β was stained by 0.1% thioflavin-S (Youmans et al., 2012). CAA was assessed using a primary antibody directed against Ab (Invitrogen, Grand Island, NY) with a standard avidin: biotinylated enzyme complex immunoperoxidase method and ABC Elite and diaminobenzidine kits (Vector Laboratories, CA), see above. Non-overlapping images of cerebral cortex (6-9 per immunostained section) were collected from 7-8 horizontal sections (40 μ m) per brain with an average of 65 images. Images were captured with an Olympus DP73 digital camera paired with cellSens software and a 10x objective to include the entire medial-lateral span of the cortex in one image. NIH ImageJ 1.48 software was used to define the region of interest (ROI) within each image, which included all cortical layers. The white matter at the edge of the cortex was excluded and served as the medial boundary. Gray scale images were thresholded for discrimination of immunopositive and negative A β zones. Total A β load represents the percentage of pixels within the cerebrocortical ROI that showed positive A β immunoreactivity. To determine CAA load, A β -immunoreactive vessels were identified morphologically. Identified vessels were analyzed only if they were visually distinct from cells with diameter >10 μ m and length of $\geq$ 20 μ m. The entirety of each immunoreactive vessel within a section was outlined to generate a CAA ROI that was contained within the larger cerebro-cortical ROI. The CAA load was calculated as the number of immunoreactive pixels within the CAA ROI and expressed as % the total pixels in the cerebrocortical ROI. Numbers of A β immunoreactive vessels within each section were determined. CAA load from each section was averaged per brain.

Microbleeds were assayed by Prussian blue staining for hemosiderin (Sullivan et al., 2008), with counterstaining by nuclear fast red (Sigma-Aldrich). Hemosiderin deposits (puncta) were individually analyzed for number and area.

2.5. ELISA. A β peptides were assayed in brain supernates (Jayaraman et al., 2012). Cerebral half-cortexes were homogenized in DEA buffer (0.2% diethylamine, 50 mm NaCl; 1 ml/200 mg tissue) with complete protease inhibitor cocktail (Sigma). After centrifugation (20,800g x 30 min), supernatants were neutralized with Tris-HCl, pH 6.2 (‘Tris extract’). Pellets were resuspended in 1% SDS-PBS and centrifuged (supernatants, ‘SDS extract’). Oligomeric A β was assayed in Tris extracts by oligo-specific MOAB-2 ELISA (Biosensis, Thebarton, Australia). A β 38, -40, -42 fragments were assayed by Peptide Panel 1 (4G8) Kit V-PLEX™ (Meso Scale Discovery, Rockville, MD).

2.6. Statistical Analyses.

Mouse: Two-way ANOVA and post-doc t-test by GraphPad Prism version 5;
Human: STATA 13 (StataCorp, College Station, TX) and SPSS 22.0. APOE allele association with number of microbleeds was analyzed by Kruskal-Wallis test. All analyses were observer-blinded.

3. Results

3.1. Microbleeds show opposite sex bias in human and mice

3.1.1. Humans. Because sex-APOE interactions for human microbleeds have not been reported, we interrogated two clinical MRI studies of well-characterized elderly for microbleeds: the ADNI Study (Alzheimer's Disease Neuroimaging Initiative), a longitudinal MRI study of a large North American cohort, and the Karolinska Imaging Dementia Study (KIDS), a cross-sectional cohort study (Methods). In both ADNI and KIDS, APOE3 homozygotes did not differ by sex in microbleeds. Both ADNI and KIDS male subjects carrying *APOE4* had more microbleeds; for both sexes, *APOE4* homozygotes had more microbleeds (Fig.1A, B, left panels). Only men showed an *APOE4* allele interaction with the microbleed burden (Table 1C). After stratification by clinical diagnosis, only the MCI and AD subjects had significant male-*APOE4* excess of microbleeds (Fig.1A, B, right panels).

3.1.2 Mice: In EFAD mice, cerebral cortex microbleeds had the opposite sex bias from humans. By Prussian blue histochemistry, females had 2-fold more microbleeds, with 5-fold greater total hemosiderin (Fig. 2A-C). Only female EFAD mice showed *APOE4* allele effects for total hemosiderin (Fig. 2C).

We also analyzed for sex effects that may be independent of FAD genes. The APOE-TR siblings without FAD transgenes in these groups also had a 2-fold female excess of microbleeds. However, their 20-fold lower levels did not show significant APOE allele effects (Fig.1S). 7 month old C57BL/6 wildtype mice from an independent sample also had cerebral microbleeds in both sexes at very low levels and of small size; these low levels did not allow resolution of possible sex differences (not shown).

3.2. EFAD associations of A β levels with microbleeds and CAA: Because microbleeds are associated with CAA in humans (Premkumar et al., 1996; Yates et al., 2014) and in mice (Zipfel et al., 2009), and because A β peptide levels drove leptomenigeal CAA in mice above a threshold A β level (Han et al., 2008; Zipfel et al., 2009), we evaluated effects of APOE alleles and sex on these relationships in EFAD mice.

3.2.1. CAA: In cerebral cortex, A β immunoreactivity exhibited a patchy pattern within morphologically identified vessels (Fig. 3A). Thioflavin S staining for fibrillar amyloid showed a similar pattern characteristic of CAA (Fig. 3A). Female EFAD mice had more A β positive vessels, with additive effects of *APOE4* (Fig. 3B). The A β load per vessel was higher in E4FAD, with no significant sex effect (Fig. 3C).

3.2.2. Plaque A β : In cerebral cortex, female EFAD mice had 2-fold more A β as plaque deposits than males for both APOE alleles (Fig.4A-C). Female sex and the *APOE4* allele had additive effects for plaque number (Fig. 4B) and for A β load (total immunoreactive area) (Fig. 4C). Plaque size differed 5-fold by sex, with no additive APOE allele effect (modal frequency size in μm^2 : 127, male E3FAD; 146, male E4; 1020, female E3; 1320, female E4).

3.2.3. Soluble A β peptides: Oligomeric A β 42 was higher in Tris-extracts of cerebral cortex (no detergents) for E4FAD mice (Fig. 4D), with effects of *APOE4* but not sex. For total soluble A β in Tris-extracts, females of both APOE alleles had higher levels of A β 38,-40, and -42, with the greatest female excess for A β 40 by >7-fold (Fig. 4D). Sequential extraction of the initial Tris-extracted pellet with SDS-PBS also showed the highest A β

levels in female E4FAD (Fig. 4F). The A β 42:40 ratios did not differ by sex or APOE allele (Fig. 4 legend).

3.2.4. Correlations of cerebrovascular pathology with A β : Most hemosiderin puncta (67%) resided within A β immunopositive deposits (Fig. 5A), which represent a minority of all A β plaques (15%). Some hemosiderin deposits (33%) were not embedded within immunodetectable A β , which we designate as 'naked microbleeds'.

Only female EFAD mice showed a significant correlation of microbleed numbers with total A β load in immunohistochemically defined plaques (Fig. 5B). The number of microbleeds was chosen for this correlation analysis in parallel with the human MRI studies (Fig.1). Since the effect of sex was stronger than *APOE* alleles, data were combined for both APOE alleles. Besides immunohistochemically detected A β , other A β fractions also showed correlation with microbleeds, again restricted to females but with lower statistical strength, in rank order: A β plaque number >PBS extracted A β 42 > PBS extracted A β 40 > oligomeric A β 42 (Fig. 5 legend). A threshold level of A β plaque load for a linear correlation with microbleeds was determined iteratively to be significant at ≥ 1.70 A β units (Fig. 5 legend). The CAA load also strongly correlated with A β plaque load for both APOE alleles, again only in females (Fig. 5C). Because different cohorts of mice were analyzed for microbleeds or CAA with A β , it was not possible to examine correlations of CAA and microbleeds in this study.

4. Discussion

We report novel sex-APOE allele interactions for cerebral cortex microbleeds and for brain A β amyloid levels with species differences. Microbleeds were analyzed from two clinical MRI imaging studies from different national populations (ADNI, U.S and Canada; KIDS, Sweden). In both ADNI and KIDS, elderly men with clinical grade symptoms of MCI or AD had 2-fold more microbleeds than women, with *APOE4* allele effects. The control groups had much fewer microbleeds in both ADNI and KIDS and did not show sex or APOE allele associations. The male bias for microbleeds confirms prior findings (Shams et al., 2015; Benedictus et al., 2015). This sex-bias is opposite to the >50% higher risk of AD in women carrying *APOE4* (Altmann et al., 2014; Corder et al., 2004).

In contrast to these human findings, EFAD mice showed female *APOE4* excess of microbleeds with correspondingly higher CAA and A β levels. The strong correlation of CAA and microbleeds with the levels of A β in EFAD female mice does not appear to generalize to human AD. Although *APOE4* carriers have excess A β (Altmann et al., 2014; Corder et al., 2004; Damoiseaux et al., 2012; Reznick et al., 2015), women have fewer microbleeds than men (Shams et al., 2015; Benedictus et al., 2015; this study). Thus, *APOE4* has sex-specificity for different causes of cognitive decline, with greater cerebrovascular contributions in men than in women. The neurobiological basis for these sex-APOE allele interactions and the species differences is unknown.

The excess of microbleeds in *APOE4* men suggests its role in the human male excess of stroke (Go et al., 2013) and of vascular disease generally (Beltran-Sanchez et al. 2015). Population-based studies (Ding et al., 2015; Jeerakathil et al., 2004; Romero et al., 2012; Sveinbjornsdottir et al., 2008) and memory clinic-based cohorts (Shams et al., 2015) also showed male bias of microbleeds, but did not assess sex-APOE4 interactions.

The differing sex bias between mice and humans for microbleeds could reflect the influence of hypertension interacting with CAA. Hypertension is more prevalent in men (Piper et al., 2014), whereas hypertension during aging is not reported for most mouse genotypes. Future studies could consider ethnic differences of sex-APOE allele interactions in cerebrovascular pathology, e.g. Asians generally have a lower prevalence of CAA than Caucasians (Chen et al., 2010).

Cerebral atrophy also shows sex differences, but with fewer sex-APOE interactions. In ADNI, older women incurred 1% faster cerebral cortex atrophy than men, with greatest effect in MCI and in proportion to APOE4 allele dose (Hua et al., 2010), but with no sex-APOE4 interaction (Xue Hua, pers. comm.). Similarly, a study of healthy elderly did not find sex-APOE effects on grey matter volume, despite strong sex-APOE interactions in functional brain connectivity (Damoiseaux et al., 2012). These sex differences also imply mechanisms of neuronal atrophy that are independent of focal vascular pathology.

The mouse models showed new cerebrovascular features. Two transgenic APOE models, EFAD and APOE-TR developed cortical microbleeds with female bias in 100% of the mice by 7 months. In contrast, only a minority of elderly human patients showed microbleeds with male bias (35% ADNI; 18.5% KIDS; Fig.1 legend). Female EFAD mice showed strong correlations of microbleeds with the total A β load above an A β threshold level (Fig. 5). These A β -microbleed correlations extend those for single FAD gene transgenic mice with endogenous murine APOE, in which vascular A β levels in leptomeningeal arteries correlated with impaired vasodilation (sex unspecified) (Han et al., 2008; Zipfel et al., 2009). These authors hypothesized that increasing microvascular A β levels above a threshold can drive a pathological progression, from impaired dilation to microaneurysms and white matter lesions (Dumas et al., 2012; Peca et al., 2013). Future human in vivo imaging studies could evaluate possible A β thresholds for microbleeds.

Intriguingly, wildtype C57BL/6 mice, the background 'wildtype' strain, also developed microbleeds within the lower range of APOE-TR, confirming Liu et al., (2014). With human transgenic A β at high levels, the EFAD mice showed a 20-fold increase of microbleeds. Because a subgroup of 18 month and older APOE-TR mice developed gross cerebral hemorrhages in association with thioflavin-positive CAA (Sullivan et al., 2008), we conclude that the endogenous murine A β is permissive for cerebrovascular pathology in the presence of human APOE. In APOE-TR mice age 7 months, we did not detect amyloid by 4G8 immunostaining or thioflavin histochemistry (not shown). Analysis of a full range of ages in APOE-TR mice may reveal transitional stages from microbleeds to gross hemorrhages and the onset age of sex-APOE allele interactions. The rapid development of A β deposits and CAA in EFAD mice by 3-7 months gives a model for A β -driven changes, distinct from neuroinflammatory changes that arise during middle-age in healthy mice.

Most microbleeds in EFAD mice were co-localized within A β deposits, also seen in another FAD model by dye-visualization of blood leaks (Tanifum et al., 2014). The correlations of microbleed numbers and of the CAA load with human A β suggest that increased A β levels drive cerebrovascular degeneration with blood-brain barrier (BBB) leakage. Moreover, extravasated blood can induce A β deposition. We observed that one-third of microbleeds did not co-localize with immunohistochemically defined A β deposits,

which we designate as ‘naked microbleeds’. Because trace bleeds from a fine needle can induce A β deposits in FAD mice (Chuang et al., 2012), we hypothesize that naked microbleeds may initiate local A β plaque genesis. Thus, the progressive leakiness of the BBB in normal human aging (Montagne et al., 2015) which is increased by *APOE4* (Bell et al., 2012) could contribute to pre-clinical A β .

CAA is incompletely documented for sex-APOE interactions. This gap may reflect different operational definitions for sporadic CAA, as a pathological entity, a clinical syndrome (e.g. symptomatic intracerebral hemorrhage, cognitive impairment), or as a neuroimaging phenotype of small vessel disease markers. *APOE4* associations with CAA as reported (Nelson et al., 2013; Premkumar et al., 1996; Walker et al., 2000; Yip, et al., 2005; Olichney et al., 2000; Berg et al., 1998), however were not replicated by others (Love et al., 2003; Xu et al., 2003). In EFAD mice, CAA showed independent effects of sex and *APOE4*. The stronger correlation of total cortical A β and CAA loads in females more than males of both APOE genotypes was paralleled by correlations of microbleeds with total A β (Fig. 5). The sex-specific correlation of both microbleeds and CAA with total A β load implies causal links to the female excess A β in human AD and in FAD mice. We note several caveats. By identifying vessels based upon morphological appearance, we may have missed smaller A β -containing vessels, thus underestimating total CAA. We also note a potential issue in interpreting findings from ADNI and KIDS groups of post-menopausal women with much lower sex steroid levels than EFAD mice at age 7 months before major decreases of sex steroids. However, young E3FAD and E4FAD female mice showed divergent A β responses to estrogen (Kunzler et al., 2014).

Could developmental variations of sex steroids alter the penetrance of *APOE4* in AD risk? In FAD mice, blood levels of sex steroids influence neurodegenerative changes (Carroll et al., 2010; Rosario et al., 2010). Besides these ‘activating’ effects, sex steroids have ‘organizational’ effects on brain development that extend to A β deposits. As shown by the Pike lab, the ‘masculinization of neonatal female FAD mice by testosterone decreased adult brain A β ; conversely, demasculinization of male neonates with flutamide increased adult A β (Rosario et al., 2010). Early sex differences include the greater vulnerability of neonatal male mouse neurons to hypoxia in primary culture (Fairbanks et al., 2013). In human congenital adrenal hyperplasia (CAH) syndrome, fetal exposure to excess androgens alters sex-linked behaviors (Hines et al., 2015) and thus might alter sex differences in CAA and AD. Cerebral arteries may also be sensitive to organizational effects of sex steroids, e.g. aneurysms, which are male biased in humans and mice, can be induced in female mice by neonatal androgenization (Zhang et al., 2012). Sex differences in cerebral vascular biology are unexplored.

Sex-*APOE4* interactions may be relevant to AD as a human-specific disease (Finch and Austad, 2015), because only humans have APOE isoforms with differing lipid binding characteristics (Fullerton et al., 2000; McIntosh et al., 2012). The *APOE4* allele was present in earlier *Homo* at least 600,000 years ago, while *APOE3* emerged about 225,000 years ago (Fullerton et al., 2000). The persistence of *APOE4* in modern populations, despite its later costs to lifespan and brain aging, may be due to benefits to young ages. *APOE4* women have higher luteal phase blood progesterone (Jasienska et al., 2015), which may enhance fertility. Moreover, *APOE4* may be adaptive in immunity by higher

cytokine responses (Finch and Morgan, 2007) and in pathogen resistance (Azevedo et al. 2014; Finch and Martin, 2015; Rougeron et al., 2013).

Species differences in CAA and microbleeds may involve both APP and APOE. Mice and humans differ in A β sequence at three sites, which decrease aggregation and cytotoxicity (Boyd-Kimball et al., 2004; De Strooper et al., 1995). Because brain amyloid fibrils are unknown in aging wildtype mice, their presence in APOE-TR mice by 18 months (Sullivan et al., 2008) implies unknown interactions of human APOE with endogenous murine APP, possibly through allele-specific affinity binding to APP that modulates A β production (Theendakara et al., 2013).

5. Conclusion

For both humans and mice, *APOE4* interacted with sex differences of microbleeds and A β levels. Comparison of human brain aging with mouse models reveals major gaps in our understanding of sex differences across species: aging men incur several-fold more microbleeds than women, opposite to male EFAD mice which had several-fold fewer. For CAA, the EFAD mice showed modest female excess in prevalence of A β -positive vessels, agreeing with some postmortem human studies. Because the mouse sex differences in brain A β and in aortic aneurysms are sensitive to organizational effects of steroids, we suggest that outcomes of cerebrovascular aging may also be shaped by sex steroids during development. This could be evaluated with postmortem brain studies of women exposed to congenital adrenal hyperplasia who show partial masculinization of behavior. Meanwhile, we need further analysis of sex-APOE interactions for CAA. The NIH directive of May 2014 to include both sexes in preclinical studies should soon expand the small data base on sex differences in brain aging. The greater risk of male *APOE4* carriers for microbleeds may be a target for genotype informed therapy to reduce this contribution to cognitive decline.

Disclosure statement

The authors have no conflicts of interest to disclose.

Acknowledgements

Experimental studies on mice were supported by the NIA: R21-AG040683 (CEF); P01-AG026572 (R.D.Brinton): Project 2 (CEF), Project 3 (CJP). EFAD mice were generously given by Mary Jo LaDu (Univ. Illinois at Chicago). APOE-TR mice were generated by Dr. Patrick Sullivan (Duke). Imaging studies were supported by the NIA: P01-AG05142 (H. Chui). Alzheimer's Disease Neuroimaging Initiative (ADNI) (NIA U01 AG-024904; DOD W81XWH-12-2-0012). ADNI is also funded by the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from: Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly; EuroImmun; F. Hoffmann-La Roche Ltd and Genentech; Fujirebio; GE Healthcare; ; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development; Medpace, Inc.; Merck & Co., Inc.; Meso Scale Diagnostics; NeuroRx Research; Neurotrack Technologies; Novartis

Pharmaceuticals; Pfizer Inc.; Piramal Imaging; Servier; Synarc; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research funds ADNI sites in Canada. Private contributions are facilitated by the Foundation for the NIH (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education. The study is coordinated by the Alzheimer's Disease Cooperative Study at UC San Diego. ADNI data are disseminated by the Laboratory for NeuroImaging at USC. Data used in preparation of this article were obtained from the ADNI database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. For ADNI investigators see: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf

References

- Allen, N., Robinson, A.C., Snowden, J., Davidson, Y.S., Mann, D.M. 2014. Patterns of cerebral amyloid angiopathy define histopathological phenotypes in Alzheimer's disease. *Neuropathol. Appl. Neurobiol.* 40, 136-148.
- Altmann, A., Tian, L., Henderson, V.W., Greicius, M.D., Alzheimer's Disease Neuroimaging Initiative, I. 2014. Sex modifies the APOE-related risk of developing Alzheimer disease. *Ann. Neurol.* 75, 563-573.
- Attems, J., Jellinger, K.A., Lintner, F. 2005. Alzheimer's disease pathology influences severity and topographical distribution of cerebral amyloid angiopathy. *Acta Neuropathol.* 110, 222-231.
- Azevedo, O.G., Bolick, D.T., Roche, J.K., Pinkerton, R.F., Lima, A.A., Vitek, M.P., Warren, C.A., Oriá, R.B., Guerrant, R.L. 2014. Apolipoprotein E plays a key role against cryptosporidial infection in transgenic undernourished mice. *PLoS One* 9(2):e89562.
- Barnes, L.L., Wilson, R.S., Bienias, J.L., Schneider, J.A., Evans, D.A., Bennett, D.A. 2005. Sex differences in the clinical manifestations of Alzheimer disease pathology. *Arch. Gen. Psych.* 62, 685-691.
- Bell, R.D., Winkler, E.A., Singh, I., Sagare, A.P., Deane, R., Wu, Z., Holtzman, D.M., et al. 2012. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. *Nature* 485, 512-516.
- Beltrán-Sánchez, H., Finch, C.E., Crimmins, E.M. 2015. The 20th Century surge of excess adult male mortality. *Proc. Nat'l. Acad. Sci.* 112, 8993-8998.
- Benedictus, M.R., Goos, J.D., Binnewijzend, M.A., Muller, M., Barkhof, F., Scheltens, P., Prins, N.D., van der Flier, W.M. 2013. Specific risk factors for microbleeds and white matter hyperintensities in Alzheimer's disease. *Neurobiol. Aging.* 34, 2488-2494.
- Berg, L., McKeel, D.W., Jr., Miller, J.P., Storandt, M., Rubin, E.H., Morris, J.C. et al. 1998. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. *Arch. Neurol.* 55, 326-335.
- Boyd-Kimball, D., Sultana, R., Mohammad-Abdul, H., Butterfield, D.A. 2004. Rodent Abeta(1-42) exhibits oxidative stress properties similar to those of human Abeta(1-42): Implications for proposed mechanisms of toxicity. *J. Alz. Dis.*, 515-525.

- 499 Caracciolo, B., Gatz, M., Xu, W., Pedersen, N.L., Fratiglioni, L. 2012. Differential
500 distribution of subjective and objective cognitive impairment in the population: a
501 nation-wide twin-study. *J. Alz. Dis.* 29, 393-403.
- 502 Carroll, J.C., Rosario, E.R., Kreimer, S., Villamagna, A., Gentzschein, E., Stanczyk, F.Z.,
503 Pike, C.J. 2010. Sex differences in beta-amyloid accumulation in 3xTg-AD mice:
504 role of neonatal sex steroid hormone exposure. *Brain. Res.* 1366, 233-245.
- 505 Chen, Y.W., Lee, M.J., Smith, E.E. 2010. Cerebral amyloid angiopathy in East and West.
506 *Int. J. Stroke.* 5, 403-411.
- 507 Chuang, J.Y., Lee, C.W., Shih, Y.H., Yang, T., Yu, L., Kuo, Y.M. 2012. Interactions
508 between amyloid-beta and hemoglobin: implications for amyloid plaque formation in
509 Alzheimer's disease. *PloS one.* 7, e33120.
- 510 Corder, E.H., Ghebremedhin, E., Taylor, M.G., Thal, D.R., Ohm, T.G., Braak, H. 2004. The
511 biphasic relationship between regional brain senile plaque and neurofibrillary tangle
512 distributions: modification by age, sex, and APOE polymorphism. *Ann. N. Y. Acad.*
513 *Sci.* 1019, 24-28.
- 514 Damoiseaux, J.S., Seeley, W.W., Zhou, J., Shirer, W.R., Coppola, G., Karydas, A. et al.
515 Alzheimer's Disease Neuroimaging, I. 2012. Gender modulates the APOE epsilon4
516 effect in healthy older adults: convergent evidence from functional brain connectivity
517 and spinal fluid tau levels. *J. Neurosci.* 32, 8254-8262.
- 518 De Strooper, B., Simons, M., Multhaup, G., Van Leuven, F., Beyreuther, K., Dotti, C.G.
519 1995. Production of intracellular amyloid-containing fragments in hippocampal
520 neurons expressing human amyloid precursor protein and protection against
521 amyloidogenesis by subtle amino acid substitutions in the rodent sequence. *EMBO*
522 *J.* 14, 4932-4938.
- 523 Ding, J., Sigurdsson, S., Garcia, M., Phillips, C.L., Eiriksdottir, G., Gudnason, V. et al.
524 2015. Risk Factors Associated With Incident Cerebral Microbleeds According to
525 Location in Older People: The Age, Gene/Environment Susceptibility (AGES)-
526 Reykjavik Study. *JAMA Neurol.* 72, 682-688.
- 527 Donham, R.S., Stetson, M.H. 1985. Neonatal androgen abolishes clock-timed
528 gonadotrophin release in prepubertal and adult female hamsters. *J. Repr. Fert.* 73,
529 215-221.
- 530 Dubal, D.B., Broestl, L., Worden, K. 2012. Sex and gonadal hormones in mouse models of
531 Alzheimer's disease: what is relevant to the human condition? *Biol. Sex. Diff.* 3, 24.
- 532 Dumas, A., Dierksen, G.A., Gurol, M.E., Halpin, A., Martinez-Ramirez, S., Schwab, K., et
533 al. 2012. Functional magnetic resonance imaging detection of vascular reactivity in
534 cerebral amyloid angiopathy. *Ann. Neurol.* 72, 76-81.
- 535 Fairbanks, S.L., Vest, R., Verma, S., Traystman, R.J., Herson, P.S. 2013. Sex stratified
536 neuronal cultures to study ischemic cell death pathways. *J. Vis. Exp.* 82, e50758.
- 537 Farrer, L.A., Cupples, L.A., Haines, J.L., Hyman, B., Kukull, W.A., Mayeux, R., et al. 1997.
538 Effects of age, sex, and ethnicity on the association between apolipoprotein E
539 genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease
540 Meta Analysis Consortium. *JAMA.* 278, 1349-1356.
- 541 Finch, C.E. 2010. Evolution of the human lifespan and diseases of aging: roles of infection,
542 inflammation, and nutrition. *Proc. Natl. Acad. Sci. USA.* 107 Suppl 1, 1718-1724.

- 543 Finch, C.E., Austad, S.N. 2015. Commentary: is Alzheimer's disease uniquely human?
544 Neurobiol. Aging. 36, 553-555.
- 545 Finch, C.E., Morgan, T.E. 2007. Systemic inflammation, infection, ApoE alleles, and
546 Alzheimer disease: a position paper. Curr. Alz. Res. 42, 185-189.

- 547 Finch, C.E., Martin, G.M. 2015. Dementias of the Alzheimer type: views through the lens of
 548 evolutionary biology suggest amyloid-driven brain aging is a trade-off with host defence.
 549 In: Evolutionary thinking in medicine: from research to policy and practice. A. Alvergne
 550 (Ed):
 551
- 552 Fleisher, A., Grundman, M., Jack, C.R., Jr., Petersen, R.C., Taylor, C., Kim, H.T., Schiller,
 553 et al. 2005. Sex, apolipoprotein E epsilon 4 status, and hippocampal volume in mild
 554 cognitive impairment. *Arch. Neurol.* 62, 953-957.
- 555 Fryer, J.D., Simmons, K., Parsadanian, M., Bales, K.R., Paul, S.M., Sullivan, P.M.,
 556 Holtzman, D.M. 2005. Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio
 557 and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor
 558 protein transgenic model. *J. Neurosci.* 25, 2803-2810.
- 559 Fullerton, S.M., Clark, A.G., Weiss, K.M., Nickerson, D.A., Taylor, S.L., et al. 2000.
 560 Apolipoprotein E variation at the sequence haplotype level: implications for the
 561 origin and maintenance of a major human polymorphism. *Am. J. Hum. Gen.* 67,
 562 881-900.
- 563 Gearing, M., Rebeck, G.W., Hyman, B.T., Tigges, J., Mirra, S.S. 1994. Neuropathology
 564 and apolipoprotein E profile of aged chimpanzees: implications for Alzheimer
 565 disease. *Proc. Natl. Acad. Sci. USA.* 91, 9382-9386.
- 566 Gilbert, J.J., Vinters, H.V. 1983. Cerebral amyloid angiopathy: incidence and complications
 567 in the aging brain. I. Cerebral hemorrhage. *Stroke.* 14, 915-923.
- 568 Go, A.S., Mozaffarian, D., Roger, V.L., Benjamin, E.J., Berry, J.D., Borden, W.B., Bravata,
 569 et al. 2003. Heart disease and stroke statistics--2013 update: a report from the
 570 American Heart Association. *Circulation.* 127, e6-e245.
- 571 Gorski, R.A. The neuroendocrinology of reproduction: an overview. 1979. *Biol. Reprod.* 20,
 572 111-127.
- 573 Greenberg, S.M., Vernooij, M.W., Cordonnier, C., Viswanathan, A., Al-Shahi Salman, R.,
 574 et al. 2009. Cerebral microbleeds: a guide to detection and interpretation. *Lancet.*
 575 *Neurol.* 8, 165-174.
- 576 Gregg NM, Kim AE, Gurol ME, Lopez OL, Aizenstein HJ, Price JC, Mathis CA, et al. 2015
 577 Incidental Cerebral Microbleeds and Cerebral Blood Flow in Elderly Individuals.
 578 *JAMA Neurol.* 72, 1021-1028. doi: 10.1001/jamaneurol.2015.1359.
- 579 Gregoire, S.M., Chaudhary, U.J., Brown, M.M., Yousry, T.A., Kallis, C., Jager, H.R.,
 580 Werring, D.J. 2009. The Microbleed Anatomical Rating Scale (MARS): reliability of
 581 a tool to map brain microbleeds. *Neurology.* 73, 1759-1766.
- 582 Han, B.H., Zhou, M.L., Abousaleh, F., Brendza, R.P., Dietrich, H.H., Koenigsnecht-
 583 Talboo, J. et al. 2008. Cerebrovascular dysfunction in amyloid precursor protein
 584 transgenic mice: contribution of soluble and insoluble amyloid-beta peptide, partial
 585 restoration via gamma-secretase inhibition. *J. Neurosci.* 28, 13542-13550.
- 586 Hines, M., Constantinescu, M., Spencer, D. 2015. Early androgen exposure and human
 587 gender development. *Biol. Sex. Diff.* 6, 3.
- 588 Hua, X., Hibar, D.P., Lee, S., Toga, A.W., Jack, C.R., Jr., Weiner, M.W et al. 2010. Sex
 589 and age differences in atrophic rates: an ADNI study with n=1368 MRI scans.
 590 *Neurobiol. Aging.* 31, 1463-1480.

- 591 Jasienska, G., Ellison, P.T., Galbarczyk, A., Jasienski, M., Kalembe-Drozd, M.,
 592 Kapiszewska, M. et al. 2015. Apolipoprotein E (ApoE) polymorphism is related to
 593 differences in potential fertility in women: a case of antagonistic pleiotropy? *Proc.*
 594 *Biol. Sci. Royal. Soc.* 282, 20142395.
- 595 Jayaraman, A., Carroll, J.C., Morgan, T.E., Lin, S., Zhao, L., Arimoto, J.M., et al. 2012.
 596 17beta-estradiol and progesterone regulate expression of beta-amyloid clearance
 597 factors in primary neuron cultures and female rat brain. *Endocrinology.* 153, 5467-
 598 5479.
- 599 Jean, S.M., Preuss, T.M., Sharma, P., Anderson, D.C., Provenzale, J.M., Strobert, E., et
 600 al. 2012. Cerebrovascular accident (stroke) in captive, group-housed, female
 601 chimpanzees. *Compar. Med.* 62, 322-329.
- 602 Jeerakathil, T., Wolf, P.A., Beiser, A., Hald, J.K., Au, R., Kase, C.S. et al. 2014. Cerebral
 603 microbleeds: prevalence and associations with cardiovascular risk factors in the
 604 Framingham Study. *Stroke.* 35, 1831-1835.
- 605 Klein, W.L., Krafft, G.A., Finch, C.E. 2014. Targeting small Abeta oligomers: the solution to
 606 an Alzheimer's disease conundrum? *Trends. Neurosci.* 24, 219-224.
- 607 Kunzler, J., Youmans, K.L., Yu, C., Ladu, M.J., Tai, L.M. 2014. APOE modulates the effect
 608 of estrogen therapy on A β accumulation EFAD-Tg mice. *Neurosci. Lett.* 560, 131-
 609 136
- 610 Lee, S.S., Stemmermann, G.N. 1978. Congophilic angiopathy and cerebral hemorrhage.
 611 *Arch. Pathn. Lab. Med.* 102, 317-321.
- 612 Love, S., Nicoll, J.A., Hughes, A., Wilcock, G.K. 2003. APOE and cerebral amyloid
 613 angiopathy in the elderly. *Neuroreport.* 14, 1535-1536.
- 614 Liu, S., Grigoryan, M.M., Vasilevko, V., Sumbria, R.K., Paganini-Hill, A., Cribbs, D.H.,
 615 Fisher, M.J. 2014 Comparative analysis of H&E and Prussian blue staining in a
 616 mouse model of cerebral microbleeds. *J. Histochem. Cytochem.* 62, 767-773.
- 617 Masuda, J., Tanaka, K., Ueda, K., Omae, T. 1988. Autopsy study of incidence and
 618 distribution of cerebral amyloid angiopathy in Hisayama, Japan. *Stroke.* 19, 205-
 619 210.
- 620 McIntosh, A.M., Bennett, C., Dickson, D., Anestis, S.F., Watts, D.P., Webster, T.H., et al.
 621 2012. The apolipoprotein E (APOE) gene appears functionally monomorphic in
 622 chimpanzees (*Pan troglodytes*). *PloS one.* 7, e47760.
- 623 Meier, I.B., Gu, Y., Guzman, V.A., Wiegman, A.F., Schupf, N., Manly, J.J. et al. 2014.
 624 Lobar microbleeds are associated with a decline in executive functioning in older
 625 adults. *Cerebrovasc. Dis.* 38, 377-383.
- 626 Montagne, A., Barnes, S.R., Sweeney, M.D., Halliday, M.R., Sagare, A.P., Zhao, Z. et al.
 627 2015. Blood-brain barrier breakdown in the aging human hippocampus. *Neuron.* 85,
 628 296-302.
- 629 Mucke, L., Selkoe, D.J. 2012. Neurotoxicity of amyloid beta-protein: synaptic and network
 630 dysfunction. *Cold. Spring. Harb. Perspect. Med.* 2, a006338.
- 631 Nelson, P.T., Pious, N.M., Jicha, G.A., Wilcock, D.M., Fardo, D.W. et al. 2013. APOE-
 632 epsilon2 and APOE-epsilon4 correlate with increased amyloid accumulation in
 633 cerebral vasculature. *J. Neuropathol. Exp. Neurol.* 72, 708-715.

- 634 Oakley, H., Cole, S.L., Logan, S., Maus, E., Shao, P., Craft, J. et al. 2006. Intraneuronal
635 beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice
636 with five familial Alzheimer's disease mutations: potential factors in amyloid plaque
637 formation. *J. Neurosci.* 26, 10129-10140.
- 638 Olichney, J.M., Hansen, L.A., Lee, J.H., Hofstetter, C.R., Katzman, R., Thal, L.J. 2000.
639 Relationship between severe amyloid angiopathy, apolipoprotein E genotype, and
640 vascular lesions in Alzheimer's disease. *Ann. N. Y. Acad. Sci.* 903, 138-143.
- 641 Payami, H., Zarepari, S., Montee, K.R., Sexton, G.J., Kaye, J.A., Bird, T.D. et al. 1996.
642 Gender difference in apolipoprotein E-associated risk for familial Alzheimer disease:
643 a possible clue to the higher incidence of Alzheimer disease in women. *Am. J. Hum.*
644 *Gen.* 58, 803-811.
- 645 Peca, S., McCreary, C.R., Donaldson, E., Kumarpillai, G., Shobha, N., Sanchez, K., et al.
646 2013. Neurovascular decoupling is associated with severity of cerebral amyloid
647 angiopathy. *Neurology.* 81, 1659-1665.
- 648 Piper, M.A., Evans, C.V., Burda, B.U., Margolis, K.L., O'Connor, E., Smith, N. et al. 2014.
649 Screening for High Blood Pressure in Adults: A Systematic Evidence Review for the
650 US Preventive Services Task Force, Rockville (MD).
- 651 Premkumar, D.R., Cohen, D.L., Hedera, P., Friedland, R.P., Kalaria, R.N. 1996.
652 Apolipoprotein E-epsilon4 alleles in cerebral amyloid angiopathy and
653 cerebrovascular pathology associated with Alzheimer's disease. *Am. J. Pathol.* 148,
654 2083-2095.
- 655 Raber, J., Wong, D., Buttini, M., Orth, M., Bellosta, S., Pitas, R.E. et al. 1998. Isoform-
656 specific effects of human apolipoprotein E on brain function revealed in ApoE
657 knockout mice: increased susceptibility of females. *Proc. Natl. Acad. Sci. USA.* 95,
658 10914-10919.
- 659 Raffai, R.L., Dong, L.M., Farese, R.V., Jr., Weisgraber, K.H. 2001. Introduction of human
660 apolipoprotein E4 "domain interaction" into mouse apolipoprotein E. *Proc. Natl.*
661 *Acad. Sci. USA.* 98, 11587-11591.
- 662 Rannikmae, K., Samarasekera, N., Martinez-Gonzalez, N.A., Al-Shahi Salman, R.,
663 Sudlow, C.L. 2013. Genetics of cerebral amyloid angiopathy: systematic review and
664 meta-analysis. *J. Neurol. Neurosurg. Psychi.* 84, 901-908.
- 665 Rasool, S., Martinez-Coria, H., Wu, J.W., LaFerla, F., Glabe, C.G. 2013. Systemic
666 vaccination with anti-oligomeric monoclonal antibodies improves cognitive function
667 by reducing Abeta deposition and tau pathology in 3xTg-AD mice. *J. Neurochem.*
668 126, 473-482.
- 669 Reijmer, Y.D., Fotiadis, P., Martinez-Ramirez, S., Salat, D.H., Schultz, A., Shoamanesh, A.
670 et al. 2015. Structural network alterations and neurological dysfunction in cerebral
671 amyloid angiopathy. *Brain.* 138, 179-188.
- 672 Resnick, S.M., Bilgel, M., Moghekar, A., An, Y., Cai, Q., Wang, M.C., et al. 2015. Changes
673 in A β biomarkers and associations with APOE genotype in 2 longitudinal cohorts.
674 *Neurobiol. Aging.* 36, 2333-2339.
- 675 Romero, J.R., Preis, S.R., Beiser, A.S., DeCarli, C., Lee, D.Y., Viswanathan, A. et al.
676 2012. Lipoprotein phospholipase A2 and cerebral microbleeds in the Framingham
677 Heart Study. *Stroke.* 43, 3091-3094.

- 678 Rosario, E.R., Carroll, J., Pike, C.J. 2012. Testosterone regulation of Alzheimer-like
679 neuropathology in male 3xTg-AD mice involves both estrogen and androgen
680 pathways. *Brain. Res.* 1359, 281-290.
- 681 Rosen, R.F., Farberg, A.S., Gearing, M., Dooyema, J., Long, P.M., Anderson, D.C. et al.
682 2008. Tauopathy with paired helical filaments in an aged chimpanzee. *J. Compar.*
683 *Neurol.* 509, 259-270.
- 684 Rougeron, V., Woods, C.M., Tiedje, K.E., Bodeau-Livinec, F., Migot-Nabias, F., Deloron,
685 P. et al. 2013. Epistatic Interactions between apolipoprotein E and hemoglobin S
686 Genes in regulation of malaria parasitemia. *PloS one.* 8, e76924.
- 687 Schmechel, D.E., Saunders, A.M., Strittmatter, W.J., Crain, B.J., Hulette, C.M., Joo, S.H.,
688 et al. 1993. Increased amyloid beta-peptide deposition in cerebral cortex as a
689 consequence of apolipoprotein E genotype in late-onset Alzheimer disease. *Proc.*
690 *Natl. Acad. Sci. USA.* 90, 9649-9653.
- 691 Shams, S., Martola, J., Granberg, T., Li, X., Shams, M., Fereshtehnejad, S.M., Cavallin, L.,
692 et al. 2015. Cerebral microbleeds: different prevalence, topography, and risk factors
693 depending on dementia diagnosis-the Karolinska Imaging Dementia Study. *Am. J.*
694 *Neuroradiol.* 36, 661-666.
- 695 Smith, D.D., Tan, X., Tawfik, O., Milne, G., Stechschulte, D.J., Dileepan, K.N. 2010.
696 Increased aortic atherosclerotic plaque development in female apolipoprotein E-null
697 mice is associated with elevated thromboxane A2 and decreased prostacyclin
698 production. *J. Physiol. Pharmac.* 61, 309-316.
- 699 Snyder HM, Corriveau RA, Craft S, Faber JE, Greenberg SM, Knopman D, et al. 2015.
700 Vascular contributions to cognitive impairment and dementia including Alzheimer's
701 disease. *Alzheimers. Dement.* 11, 710-717.
- 702 Sturchler-Pierrat, C., Staufenbiel, M. 2000. Pathogenic mechanisms of Alzheimer's
703 disease analyzed in the APP23 transgenic mouse model. *Ann. N. Y. Acad. Sci.* 920,
704 134-139.
- 705 Sullivan, P.M., Mace, B.E., Estrada, J.C., Schmechel, D.E., Alberts, M.J. 2008. Human
706 apolipoprotein E4 targeted replacement mice show increased prevalence of
707 intracerebral hemorrhage associated with vascular amyloid deposition. *J. Stroke.*
708 *Cerebrovasc. Dis.* 17, 303-311.
- 709 Sullivan, P.M., Mezdour, H., Aratani, Y., Knouff, C., Najib, J., Reddick, R.L. et al. 1997.
710 Targeted replacement of the mouse apolipoprotein E gene with the common human
711 APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. *J.*
712 *Biol. Chem.* 272, 17972-17980.
- 713 Sveinbjornsdottir, S., Sigurdsson, S., Aspelund, T., Kjartansson, O., Eiriksdottir, G.,
714 Valtysdottir, B. et al. 2008. Cerebral microbleeds in the population based AGES-
715 Reykjavik study: prevalence and location. *J. Neurol. Neurosurg. Psych.* 79, 1002-
716 1006.
- 717 Tanifum, E.A., Starosolski, Z.A., Fowler, S.W., Jankowsky, J.L., Annapragada, A.V. 2014.
718 Cerebral vascular leak in a mouse model of amyloid neuropathology. *J. Cereb.*
719 *Blood. Flow. Metab.* 34, 1646-1654.

- Theendakara, V., Patent, A., Peters Libeu, C.A., Philpot, B., Flores, S., Descamps, O., et al. 2013. Neuroprotective Sirtuin ratio reversed by ApoE4. *Proc. Natl. Acad. Sci. USA.* 110, 18303-18308.
- Vamathevan, J.J., Hasan, S., Emes, R.D., Amrine-Madsen, H., Rajagopalan, D., Topp, S.D et al. 2008. The role of positive selection in determining the molecular cause of species differences in disease. *BMC. Evol. Biol.* 8, 273.
- Vest, R.S., Pike, C.J. 2013. Gender, sex steroid hormones, and Alzheimer's disease. *Horm. Behav.* 63, 301-307.
- Walker, L.C., Pahnke, J., Madauss, M., Vogelgesang, S., Pahnke, A., Herbst, E.W., et al. 2000. Apolipoprotein E4 promotes the early deposition of Abeta42 and then Abeta40 in the elderly. *Acta. Neuropathol.* 100, 36-42.
- Wardlaw, J.M., Smith, E.E., Biessels, G.J., Cordonnier, C., Fazekas, F., Frayne, R., et al. 2013. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. *Lancet. Neurol.* 12, 822-838.
- Xu, D., Yang, C., Wang, L. 2003. Cerebral amyloid angiopathy in aged Chinese: a clinico-neuropathological study. *Acta. Neuropathol.* 106, 89-91.
- Yates, P.A., Desmond, P.M., Phal, P.M., Steward, C., Szoeki, C., Salvado, O. et al. 2014. Incidence of cerebral microbleeds in preclinical Alzheimer disease. *Neurology.* 82, 1266-1273.
- Yip, A.G., McKee, A.C., Green, R.C., Wells, J., Young, H., Cupples, L.A., Farrer, L.A. 2005. APOE, vascular pathology, and the AD brain. *Neurology.* 65, 259-265.
- Youmans, K.L., Tai, L.M., Nwabuisi-Heath, E., Jungbauer, L., Kanekiyo, T., Gan, M., et al. 2012. APOE4-specific changes in Abeta accumulation in a new transgenic mouse model of Alzheimer disease. *J. Biol. Chem.* 287, 41774-41786.
- Zhang, X., Thatcher, S.E., Rateri, D.L., Bruemmer, D., Charnigo, R., Daugherty, A., Cassis, L.A. 2012. Transient exposure of neonatal female mice to testosterone abrogates the sexual dimorphism of abdominal aortic aneurysms. *Circulation. Res.* 110, e73-e85.
- Zipfel, G.J., Han, H., Ford, A.L., Lee, J.M. 2009. Cerebral amyloid angiopathy: progressive disruption of the neurovascular unit. *Stroke.* 40, S16-19.

Figure Legends

Figure 1. Human male *APOE4* carriers have more cerebral microbleeds.

MRI analysis of ADNI and KIDS clinical cohorts showed male excess of microbleeds, increasing with *APOE4* allele dose. *APOE3* did not differ by sex in microbleed numbers. In both studies, a minority of subjects had microbleeds: ADNI, 35%; KIDS, 19%. Data are shown as total sample (left panel) and by diagnostic group (right) for mean number of microbleeds $\pm$ 95% CI. Table 1 shows statistical findings and subject numbers by diagnostic group and *APOE* allele. Both studies used a negative binomial regression model adjusted for age and a diagnostic group specified for each study. Ctrl: control group; MCI: mild cognitive impairment; AD: Alzheimer Disease. **A.** ADNI, the Alzheimer Disease Neuroimaging Initiative, representing the U.S.A and Canada. Total subjects (N= 658); clinical diagnosis: Ctrl, cognitively normal; MCI, mild cognitive impairment; and clinical AD. MRI sequence: GRE-T2*; MRI field strength, 3T. **B.** KIDS, Karolinska Imaging Dementia Study. Total subjects (N=448); clinical diagnosis: Ctrl, subjective cognitive impairment (not clinical grade); MCI, and clinical AD; same MRI as ADNI. *, *APOE* allele dose effect; #, *APOE* allele- male sex interaction (see Table1 for details).

Figure 2. Microbleeds in cerebral cortex of EFAD mice: female excess is additive with *APOE4*.

A. Microbleeds visualized as extravasated hemosiderin by Prussian blue histochemistry in cerebral cortex sagittal sections (0.5-2 mm lateral from midline; counterstained by nuclear fast red; scale bar 50 μ m). The inset shows cortical layers I and III. **B.** Number of microbleeds per 100 mm² of cortical area for EFAD mice. Female excess was observed in both EFAD mice. **C.** Hemosiderin load (total Prussian blue area, %) showed female excess and additivity with *APOE4* in EFAD. * $p < 0.05$; ** $p < 0.01$; **** $p < 0.001$. Male microbleeds did not differ by *APOE* allele.

Figure 3. Cerebrovascular amyloid in EFAD mice shows female excess.

A. Cortical vessels immunopositive for A β (upper panels) and for thioflavin-S (lower panels) in EFAD mice. Scale bars: 50 μ m. **B.** The number of A β -immunopositive (A β -IR) vessels was higher in females, with additive effects of *APOE4*. **C.** CAA load of A β within vessels was higher in *E4FAD* mice but did not differ by sex. Mean $\pm$ SEM, N=6-8/group ** $p < 0.01$; *** $p < 0.005$.

Figure 4. Levels of plaque and soluble A β show female excess in EFAD mice.

A. Cerebral cortex sagittal sections (0.5-2 mm lateral from midline) were immunostained for A β (4G8 antibody); middle panels, Cresyl violet histochemistry showing cortical layers; scale bar, 100 μ m. **B.** Number of plaques per per 100 mm² of cortical area **C.** A β load, total plaque A β immunostaining. The subiculum had similar female and *APOE4* excess A β plaque (not shown). The sex-apoE interaction was significant for A β load ($p = 0.02$). **D-E.** Soluble A β peptides in cerebral cortex. Oligomeric A β 42 in PBS extract (oligo-specific ELISA) differed by *APOE* allele, but not by sex (MOAB-1 ELISA). Total A β peptides (multiplex ELISA) showed female excess, with additive effects for *APOE4* for A β 38, A β 40, and A β 42. PBS extracts had consistently 2-fold more A β 40 than A β 42 (A β 40:42 ratio male: *E3*, 1.5 $\pm$ 0.1, *E4*, 1.7 $\pm$ 0.5; female: *E3*, 2.6 $\pm$ 0.4, *E4*, 1.6 $\pm$ 0.1), whereas the ratio was closer to 1 in SDS extracts (male: *E3*, 1.5 $\pm$ 0.1, *E4*, 1.7 $\pm$ 0.5; female: *E3*, 2.6 $\pm$ 0.4, *E4*, 1.6 $\pm$ 0.1). Sex-apoE allele interactions were significant for total soluble A β levels in both the PBS (A β 38, $p < 0.01$; A β 40, $p < 0.01$; A β 42, $p = 0.001$) and SDS extractions (A β 40, $p < 0.005$; A β 42 $p < 0.01$). Mean $\pm$ SEM, N=6-8/group. CC: corpus callosum; * $p < 0.05$; ** $p < 0.01$, *** $p < 0.005$.

801 **Figure 5. A β total load correlated with microbleeds and CAA only in EFAD females.**
 802 **A.** Cerebral cortex histochemistry co-staining for A β (4G8 antibody, brown) and
 803 microbleeds (Prussian Blue, hemosiderin); these images show the diverse morphology of
 804 hemosiderin cores within A β deposits, scale bars, 50 μ m. Middle panel shows particular
 805 from left panel (black box). **B.** The number of microbleeds correlated most strongly with
 806 total A β plaque load for female EFAD mice, but not males, in rank order of total plaque A β
 807 load (M, $r^2=0.09$, $p=0.3$; F, $r^2=0.89$, $p<0.001$) >PBS-extracted A β 42 (M, $r^2=0.002$, $p=0.9$; F,
 808 $r^2=0.64$, $p<0.01$) and PBS extracted A β 40 (M, $r^2=0.002$, $p=0.9$; F, $r^2=0.47$, $p<0.05$), >
 809 oligomeric A β 42 (M, $r^2=0.003$, $p=0.9$; F, $r^2=0.27$, $p=0.15$). The threshold level of total A β
 810 for linear correlation with microbleed numbers was determined iteratively: A β ≥ 1.70 , $t =$
 811 8.6294 , $df = 10$, $p = 6.03e-06$; A β < 1.70 , $t = 0.4536$, $df = 5$, $p = 0.6692$. **C.** CAA load
 812 correlated with total A β load in females, but not males (M, $r^2=0.22$, $p=0.1$; F, $r^2=0.75$,
 813 $p<0.001$). CAA load represents 1.8% of the total A β load in females and 5.3% in males.
 814 Removal of one male outlier in the A β plaque load yields a significant correlation ($p=0.05$);
 815 nonetheless, the resulting r^2 value for males (0.34) would still be below the females (0.75).

816 **Figure 1S. Additive effect of human APOE and FAD mutations on number of**
 817 **microbleeds.** Number of microbleeds per unit of cortical area (100 mm^2) for APOE-TR
 818 (APOE3, APOE4) and EFAD mice. Female excess was observed in APOE4 mice and both
 819 EFAD mice. Mean $\pm$ SEM, N=6-8/group; * $p<0.05$

820

821

Table 1. Statistical analysis of human cohorts

A. Demography

	ADNI (%)	KIDS (%)
Patients	658	448
Age (years)		
Total	48-91, median 73 (IQR: 67-78)	36-88, median 62 (IQR 57-66)
Control	56-90, median 74 (IQR: 70-79)	36-79, median 57 (IQR 53-63)
MCI	48-89, median 72 (IQR: 66-77)	40-81, median 63 (IQR: 57-67)
AD	56-91, median 76 (IQR: 70-80)	50-88, median 64 (IQR: 60-72)
Male	363 (53)	183 (41)
Patients with microbleeds	228 (35)	88 (19)
APOE 3/3	335 (51)	206 (46)
APOE 3/4	249 (38)	174 (39)
APOE 4/4	74 (11)	68 (15)
Control	166 (25)	144 (32)
MCI	402 (61)	152 (34)
AD	90 (14)	152 (34)

B. Clinical Diagnosis

	ADNI			KIDS		
APOE allele	E3/E3	E3/E4	E4/E4	E3/E3	E3/E4	E4/E4
Ctrl (M/F)	58/51	22/30	3/2	26/47	21/36	2/4
MCI (M/F)	106/95	91/63	29/18	27/23	22/41	10/29
AD (M/F)	10/15	24/19	15/7	38/38	29/25	8/15

C. Sex differences

	ADNI		KIDS	
Male excess				
	coeff	p-value	coeff	p-value
Total	0.61	0.003	1.7	<0.001
Control			1.73	<0.001
MCI			1.12	<0.001
AD	0.9	0.07	2.02	<0.001

D. APOE allele interactions

	ADNI				KIDS			
APOE allele	E3/E4		E4/E4		E3/E4		E4/E4	
	coeff	p-value	coeff	p-value	coeff	p-value	coeff	p-value
APOE allele dose *								
Total	1.4	0.003	2.4	<0.001	0.6	<0.001	0.8	<0.001
Control					2.26	<0.001		
MCI	1.7	<0.001	2.2	<0.001			1.2	<0.001
AD	1.2	0.04	3.1	<0.001	0.69	0.004		
APOE allele- MALE sex interaction #								
Total	1.6	<0.001	1.6	=0.007	0.6	<0.001	0.8	0.02
Control					1.8	0.06		
MCI	1.9	0.001					1.2	0.04
AD			3.0	=0.02	1.6	<0.001	0.7	<0.08

Coeff: coefficient of regression analysis. Non-significant values are not shown.

Figure(s)

A. ADNI

Clinical Diagnosis

B. KIDS

Clinical Diagnosis

□ M
■ F

Figure(s)

Figure(s)

Figure(s)

Figure(s)